


# PRODUCT INFORMATION



**TG003**

Item No. 10398

**CAS Registry No.:** 300801-52-9  
**Formal Name:** 1-(3-ethyl-5-methoxy-2(3H)-benzothiazolylidene)-2-propanone  
**MF:** C<sub>13</sub>H<sub>15</sub>NO<sub>2</sub>S  
**FW:** 249.3  
**Purity:** ≥95%  
**Stability:** ≥2 years at -20°C  
**Supplied as:** A crystalline solid  
**UV/Vis.:** λ<sub>max</sub>: 215, 250, 362 nm



## Laboratory Procedures

For long term storage, we suggest that TG003 be stored as supplied at -20°C. It should be stable for at least two years.

TG003 is supplied as a crystalline solid. A stock solution may be made by dissolving the TG003 in the solvent of choice. TG003 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of TG003 in these solvents is approximately 15 mg/ml.

TG003 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, TG003 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. TG003 has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

Cdc2-like kinase (Clk), among a number of other kinases, phosphorylates serine/arginine-rich proteins which play a role in alternative splicing of pre-mRNA. The Clk family consists of four members, which include Clk1/Sty and Clk2-4. TG003 is a novel benzothiazole compound that demonstrates potent inhibition of Clk1/Sty and Clk4 with IC<sub>50</sub> values of 20 and 15 nM, respectively.<sup>1</sup> TG003 exhibits considerably weaker inhibition of Clk2 and Clk3 (IC<sub>50</sub> = 200 nM and >10 μM, respectively).<sup>1</sup> Through suppression of Clk-mediated phosphorylation, TG003 inhibits SF2/ASF-dependent splicing of β-globin pre-mRNA at 1 μM *in vitro*.<sup>1</sup> At 10 μM, TG003 rescues the embryonic defects induced by excessive Clk activity in *Xenopus*.<sup>1</sup>

## Reference

1. Muraki, M., Ohkawara, B., Hosoya, T., *et al.* Manipulation of alternative splicing by a newly developed inhibitor of Clks. *J. Biol. Chem.* **279(23)**, 24246-24254 (2004).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/07/2016

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM